H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

Original reporting
Published Oct 30, 2026, 11:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PHAT
Bullish
high confidence
Mentioned
$PHAT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PHATBullishMed
01

Why it matters

The earnings beat and higher price target may attract momentum traders, but execution risk remains.

02

Market read

The news provides fresh earnings data and an upgraded target for PHAT, offering a potential short‑term trade idea.

03

What to watch

Potential regulatory hurdles for VOQUEZNA and the modest revenue miss could temper upside.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Phathom Pharmaceuticals (PHAT) is a micro‑cap biotech focused on GI disorders, recently reporting Q3 2026 results and receiving an analyst upgrade.

Company-level read

Ticker impact

$PHATBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating and raised the price target to $26 after Phathom's Q3 2026 earnings beat expectations on EPS and highlighted commercial momentum.

Expected impact

likely upward pressure as the market prices in the higher target and earnings beat.

Evidence & confidence

The fresh earnings numbers and upgraded target are new information that can drive buying interest.

Market effects

Positive signal for the GI‑focused biotech sector as a peer shows revenue growth and profitability path.

Limited to US small‑cap biotech investors.

Minimal; primarily affects niche biotech investors.

Counterpoint

The stock remains far below the $26 target and may face execution risk on its pipeline.

Key entities

  • Phathom Pharmaceuticals

    NASDAQ‑listed biotech developing VOQUEZNA for GERD/NERD.

  • H.C. Wainwright

    Equity research firm that reiterated a Buy rating and raised the target.

Related articles

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.

$PHATMedAI 8/10

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G